Voronoi, Inc.

Equities

A310210

KR7310210000

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
34,100 ^KRW	+2.56%		+5.08%	-36.85%

2023	Voronoi, Inc.(KOSDAQ:A310210) added to S&P Global BMI Index	CI
2023	Voronoi to Raise 45 Billion Won From Shares Issuance; Shares Jump 9%	MT

Voronoi, Inc. has withdrawn its IPO in the amount of KRW 130 billion.

March 16, 2022 at 12:00 am EDT

Voronoi, Inc. has withdrawn its IPO in the amount of KRW 130 billion.

Security Name: Shares
Security Type: Common Stock
Securities Offered: 2,000,000
PriceRange: KRW 50000 to KRW 65000

Transaction Features: Sponsor Backed Offering

Latest news about Voronoi, Inc.

Voronoi, Inc.(KOSDAQ:A310210) added to S&P Global BMI Index	23-09-18	CI
Voronoi to Raise 45 Billion Won From Shares Issuance; Shares Jump 9%	23-06-20	MT
Voronoi, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Voronoi Signs $482 Million Deal to Develop Oral Kinase Inhibitor	22-09-14	MT
METiS Therapeutics Announces Pan-RAF Inhibitor License Agreement with Voronoi	22-09-13	CI
Voronoi, Inc. has completed an IPO in the amount of KRW 52 billion.	22-06-17	CI
Voronoi, Inc. has filed an IPO in the amount of KRW 59.8 billion.	22-05-13	CI
Voronoi, Inc. has withdrawn its IPO in the amount of KRW 130 billion.	22-03-16	CI
Voronoi, Inc. has filed an IPO.	21-08-30	CI
ORIC Pharmaceuticals, Inc. Enters into an Exclusive License Agreement with Voronoi, Inc	20-10-19	CI

Chart Voronoi, Inc.

Duration

Period

More charts

Company Profile

Voronoi Inc is a Korea-based company principally engaged in the research and development of new drug candidates. The Company is principally engaged in the technology transfer of new drug candidates prior to electroclinical clinical trials. The Company is principally engaged in the research and development of kinase inhibitor as well as others. In addition, the Company is also engaged in the building and supply of new drug development platforms based on artificial intelligence (AI) and research results.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

34,100 KRW

Average target price

85,000 KRW

Spread / Average Target

+149.27%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VORONOI, INC.	-36.85%	436M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B

Other Biotechnology & Medical Research